WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2010025308) INHIBITORS OF DUTPASE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2010/025308    International Application No.:    PCT/US2009/055264
Publication Date: 04.03.2010 International Filing Date: 27.08.2009
IPC:
A61K 31/513 (2006.01), A61K 31/505 (2006.01)
Applicants: UNIVERSITY OF SOUTHERN CALIFORNIA [US/US]; USC Stevens Hughes Center, Suite EEB 131 3740 Mcclintock Avenue Los Angeles, CA 90089-2561 (US) (For All Designated States Except US).
LANDNER, Robert, D. [US/US]; (US) (For US Only).
NEMATI, Nouri [US/US]; (US) (For US Only)
Inventors: LANDNER, Robert, D.; (US).
NEMATI, Nouri; (US)
Agent: MCCLURE, Lawrence, J.; Hogan & Hartson L.L.P. 1999 Avenue Of The Stars, Suite 1400 Los Angeles, CA 90067 (US)
Priority Data:
61/092,330 27.08.2008 US
Title (EN) INHIBITORS OF DUTPASE
(FR) INHIBITEURS DE DUTPASE
Abstract: front page image
(EN)Evidence demonstrating that elevated expression of dUTPase protects breast cancer cells from the expansion of the intracellular uracil pool, translating to reduced growth inhibition following treatment with 5-FU is provided. The implementation of in silico drug development techniques to identify and develop small molecule inhibitors of dUTPase are reported. As 5-FU and the oral 5-FU pro-drug capecitabine remain central agents in the treatment of a variety of malignancies, the clinical utility of a small molecule inhibitor to dUTPase represents a viable strategy to improve the clinical efficacy of these mainstay chemotherapeutic agents.
(FR)Selon l'invention, il s'avère que l'expression élevée de dUTPase protège des cellules du cancer du sein de l'expansion de la masse commune d'uracile intracellulaire, passant à une inhibition de la croissance réduite à la suite du traitement avec 5-FU. L' invention concerne également la mise en oeuvre de techniques de développement de médicaments in silico pour identifier et développer des inhibiteurs à petites molécules de dUTPase. Comme 5-FU et la capécitabine du promédicament 5-FU par voie orale restent des agents centraux du traitement d'une variété de tumeurs malignes, l'utilité clinique d'un inhibiteur à petite molécule pour dUTPase représente une stratégie viable pour améliorer l'efficacité clinique de ces agents chimiothérapiques essentiels.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)